Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser*, M. Arad

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

149 Scopus citations

Fingerprint

Dive into the research topics of 'Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science